Search

Your search keyword '"Eymard-Duvernay, Sabrina"' showing total 305 results
Start Over Author "Eymard-Duvernay, Sabrina"
305 results on '"Eymard-Duvernay, Sabrina"'

2. An optimized strategy triggered at the 2nd immunization visit to prevent HIV acquisition by breastfeeding: a phase 2 trial in Burkina Faso (PREVENIR-PEV)

Author

Mennecier, Anaïs, Sakana, Béninwendé Leticia Delphine, D’Ottavi, Morgana, Tassembedo, Souleymane, Moles, Jean-Pierre, Kania, Dramane, Taofiki, Ajani Ousmane, Kadeba, Franck Edgar, Diallo, Ibrahima, Eymard-Duvernay, Sabrina, Meda, Nicolas, Mosqueira, Beatriz, Fao, Paulin, Nagot, Nicolas, and Vande Perre, Philippe

Published
2024
Full Text
View/download PDF

3. Combination of serological and cytokine release assays for improved diagnosis of childhood tuberculosis in Zambia (PROMISE-TB)

Author

Tuaillon, Edouard, Mwyia, Mwiya, Bollore, Karine, Pisoni, Amandine, Rubbo, Pierre-Alain, Richard, Matthias, Kremer, Laurent, Tonga, Maria M.W., Chanda, Duncan, Peries, Marianne, Vallo, Roselyne, Eymard-Duvernay, Sabrina, D'Ottavi, Morgana, Kankasa, Chipepo, de Perre, Philippe Van, Moles, Jean-Pierre, and Nagot, Nicolas

Published
2024
Full Text
View/download PDF

4. Defining a Dichotomous Indicator for Population-Level Assessment of Dietary Diversity Among Pregnant Adolescent Girls and Women: A Secondary Analysis of Quantitative 24-h Recalls from Rural Settings in Bangladesh, Burkina Faso, India, and Nepal

Author

Verger, Eric O, Eymard-Duvernay, Sabrina, Bahya-Batinda, Dang, Hanley-Cook, Giles T., Argaw, Alemayehu, Becquey, Elodie, Diop, Loty, Gelli, Aulo, Harris-Fry, Helen, Kachwaha, Shivani, Kim, Sunny S, Nguyen, Phuong Hong, Saville, Naomi M, Tran, Lan Mai, Zagré, Rock R, Landais, Edwige, Savy, Mathilde, Martin-Prevel, Yves, and Lachat, Carl

Published
2024
Full Text
View/download PDF

5. Prevention of mother-to-child transmission of HIV at the second immunization visit: a cross-sectional study, Burkina Faso/Prevention de la transmission du VIH de la mere a l'enfant lors de la seconde visite de vaccination: etude transversale, Burkina Faso/Prevencion de la transmision maternofilial del VIH en la segunda visita de vacunacion; un estudio transversal en Burkina Faso

Author

Sakana, Beninwende Leticia Delphine, Mennecier, Anais, Fao, Paulin, Tassembedo, Souleymane, Moles, Jean- Pierre, Kania, Dramane, Taofiki, Ajani Ousmane, Kadeba, Franck Edgar, Diallo, Ibrahima, Eymard-Duvernay, Sabrina, D'Ottavi, Morgana, Meda, Nicolas, Mosqueira, Beatriz, Van de Perre, Philippe, and Nagot, Nicolas

Subjects
HIV (Viruses) -- Prevention, Vaccination, HIV testing, Infants, Highly active antiretroviral therapy, Health, World Health Organization, United Nations. Children's Fund
Abstract

Objective To evaluate the performance of the cascade of activities for prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) at the second immunization visit in Burkina Faso. Methods In a cross-sectional study, we recruited mothers attending the second immunization visit for their infant in 20 health centres of Bobo-Dioulasso city, Burkina Faso over 12 months (2019-2020). We administered a short questionnaire to 14 176 mothers and performed HIV serological tests on mothers who had not been tested in the last 3 months. All mothers were asked about their attendance for antenatal care and HIV rapid testing. HIV-infected mothers were also asked about the timing of their HIV diagnosis, antiretroviral therapy, pre-exposure prophylaxis initiation at birth and infant diagnosis of HIV. Findings Of 14 136 respondents, 13 738 (97.2%) had at least one HIV serological test in their lifetime. Of 13 078 mothers who were never tested or were HIV-negative, 12 454 (95.2%) were tested during or after their last pregnancy. Among HIV-infected mothers already aware of their status, 110/111 (99.1%) women were on antiretroviral therapy. Among HIV-exposed infants, 84/101 (83.2%) babies received 6 weeks of antiretroviral prophylaxis at birth and 58/110 (52.7%) had a blood sample collected for early infant diagnosis. Only two mothers received their child's test results at the time of the second immunization visit. Four mothers were newly diagnosed as HIV-positive during the study. Conclusion Collecting data at the second immunization visit, a visit rarely missed by mothers, could be useful for identifying gaps in the PMTCT cascade in settings where mothers are difficult to reach, such as in low-income countries with intermediate or low HIV prevalence. Objectif Evaluer les performances de la cascade d'activites liees a la prevention d'une transmission de la mere a l'enfant (PTME) du virus de l'immunodeficience humaine (VIH) lors de la seconde visite de vaccination au Burkina Faso. Methodes Dans le cadre de notre etude transversale, nous avons recrute des meres se rendant a la seconde visite de vaccination de leur nourrisson dans 20 centres de sante de la ville de Bobo-Dioulasso (Burkina Faso) pendant 12 mois (2019-2020). Nous avons soumis un bref questionnaire a 14 176 meres et effectue un test serologique de depistage du VIH sur celles n'ayant pas ete testees au cours des trois derniers mois. Toutes ont ete interrogees sur leur participation aux soins prenatals et aux tests rapides de detection du VIH. Nous avons egalement demande aux meres infectees par le VIH des informations sur la date du diagnostic, le traitement antiretroviral, le debut de la prophylaxie avant exposition a la naissance et le depistage du VIH chez le nourrisson. Resultats Sur un total de 14 136 participantes, 13 738 (97,2%) ont subi au moins un test serologique de depistage du VIH au cours de leur vie. Sur 13 078 meres jamais testees ou seronegatives, 12 454 (95,2%) ont ete testees au cours ou a l'issue de leur derniere grossesse. Parmi les meres seropositives connaissant deja leur statut, 110 sur 111 (99,1%) suivaient un traitement antiretroviral. Et parmi les nourrissons exposes au VIH, 84 sur 101 (83,2%) ont recu une prophylaxie antiretrovirale durant les 6 semaines suivant leur naissance, tandis qu'un echantillon de sang a ete preleve chez 58 sur 110 (52,7%) afin de poser un diagnostic precoce. Seules deux meres avaient obtenu les resultats des tests de leur enfant au moment de la seconde visite de vaccination. Enfin, quatre meres ont ete diagnostiquees seropositives pendant l'etude. Conclusion Colliger des donnees lors de la seconde visite de vaccination, a laquelle les meres sont generalement presentes, pourrait s'averer utile pour identifier les faiblesses dans la cascade d'activites liees a la PTME dans les regions oU il est difficile d'entrer en contact avec les meres, notamment dans les pays a revenu faible oU la prevalence du VIH est faible a moderee. Objetivo Evaluar el rendimiento de la serie de actividades de prevencion de la transmision maternofilial (PTMF) del virus de la inmunodeficiencia humana (VIH) en la segunda visita de vacunacion en Burkina Faso. Metodos En un estudio transversal, se reclutaron madres que asistian a la segunda visita de vacunacion de su bebe en 20 centros sanitarios de la ciudad de Bobo-Dioulasso, Burkina Faso, durante 12 meses (20192020). Se realizo un breve cuestionario a 14 176 madres y se llevaron a cabo pruebas serologicas del VIH a las madres que no se habian hecho la prueba en los ultimos 3 meses. Se pregunto a todas las madres sobre su asistencia a la atencion prenatal y a la prueba rapida del VIH. Tambien se pregunto a las madres infectadas por el VIH sobre el momento de su diagnostico de VIH, el tratamiento antirretrovirico, el inicio de la profilaxis previa a la exposicion en el momento del nacimiento y el diagnostico de VIH en el bebe. Resultados De 14 136 encuestadas, 13 738 (97,2%) se hicieron al menos una prueba serologica del VIH a lo largo de su vida. De las 13 078 madres que nunca se habian sometido a la prueba o no estaban infectadas por el VIH, 12 454 (95,2%) se sometieron a la prueba durante o despues de su ultimo embarazo. Entre las madres infectadas por el VIH que ya conocian su estado, 110/111 (99,1%) mujeres estaban en tratamiento antirretrovirico. Entre los bebes expuestos al VIH, 84/101 (83,2%) recibieron 6 semanas de profilaxis antirretrovirica al nacer y a 58/110 (52,7%) se les tomo una muestra de sangre para el diagnostico temprano del bebe. Solo dos madres recibieron los resultados de las pruebas de sus hijos en el momento de la segunda visita de vacunacion. Cuatro madres recibieron un diagnostico reciente como infectadas por el VIH durante el estudio. Conclusion La recopilacion de datos en la segunda visita de vacunacion, una visita a la que rara vez faltan las madres, podria ser util para identificar las deficiencias del proceso de PTMF en lugares donde es dificil llegar a las madres, como en los paises de bajos ingresos con una prevalencia intermedia o baja del VIH., Introduction Despite progress in preventing new paediatric human immunodeficiency virus (HIV) infections, the goal of eliminating mother-to-child transmission remains unattained. (1) According to an estimate from the United Nations Children's [...]

Published
2022
Full Text
View/download PDF

6. Corrigendum to ‘Defining a Dichotomous Indicator for Population-Level Assessment of Dietary Diversity Among Pregnant Adolescent Girls and Women:…’ [Curr. Dev. Nutr. 8 (2024) 102053]

Author

Verger, Eric O, primary, Eymard-Duvernay, Sabrina, additional, Bahya-Batinda, Dang, additional, Hanley-Cook, Giles T, additional, Argaw, Alemayehu, additional, Becquey, Elodie, additional, Diop, Loty, additional, Gelli, Aulo, additional, Harris-Fry, Helen, additional, Kachwaha, Shivani, additional, Kim, Sunny S, additional, Nguyen, Phuong Hong, additional, Saville, Naomi M, additional, Tran, Lan Mai, additional, Zagré, Rock R, additional, Landais, Edwige, additional, Savy, Mathilde, additional, Martin-Prevel, Yves, additional, and Lachat, Carl, additional

Published
2024
Full Text
View/download PDF

9. Epidaure Market–Effectiveness and transferability of a school-based intervention to improve healthy and sustainable food choices by schoolchildren: Protocol of a randomized controlled trial and qualitative study.

Author

Curnier, Aurélie, Cholley-Gomez, Marie, Lecêtre, Florian, Peteuil, Audrey, Meunier-Beillard, Nicolas, Fonquerne, Leslie, Darras, Lucy, Eymard-Duvernay, Sabrina, Méjean, Caroline, Delpierre, Cyrille, Cottet, Vanessa, and Cousson-Gélie, Florence

Subjects
RANDOMIZED controlled trials, CLUSTER randomized controlled trials, DIETARY patterns, SCHOOL food, SCIENTIFIC literature, FOOD preferences, SCHOOL children
Abstract

Context: At least 40% of cancers are linked to environmental or behavioral factors, and dietary behavior appears to be a major lever. Epidaure Market is a prevention initiative developed using a method for co-constructing health promotion initiatives and prevention programs that stratifies evidence from the scientific literature and combines it with experiential knowledge (DEVA, TPB, BCT). It promotes a sustainable diet (i.e., healthy, ecological and ethical nutrition) among 5th and 4th grade students during the crucial period of adolescence, when these behaviors are often far from the recommendations. Method: The protocol implemented was carried out in 72 middle school classes in the Montpellier and Dijon academies. The intervention included teaching sessions and a virtual supermarket game, integrated into the school curriculum and delivered by science teachers. Effectiveness is tested in a cluster randomized controlled trial with 3 evaluation times (pre- and post-intervention and 1 follow-up). The study also includes an implementation assessment, with process analysis and implementation elements, as well as a transferability assessment based on key functions (FIC model and Astaire grid). Expected outcomes: The study is still underway within the school. The primary expected outcome is a positive influence on the motives underlying food choices to move towards a sustainable diet. Secondary expectations involve changes in variables such as self-efficacy and perceived social norms, as well as an increase in knowledge about healthy eating. We also expect the qualitative approaches to provide information on the deployment process in the new territories. Discussion: The study aims not only to demonstrate the effectiveness of Epidaure Market, but also to identify the optimal conditions for its nationwide implementation in France's middle schools. Ultimately, the initiative aims to help reduce the incidence of cancer by promoting healthier eating habits among teenagers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and Southeast Asian countries.

Author

Aghokeng, Avelin F, Ngo-Giang-Huong, Nicole, Huynh, Thu H K, Dagnra, Anoumou Y, Toni, Thomas D'Aquin, Maiga, Almoustapha I, Dramane, Kania, Eymard-Duvernay, Sabrina, Chaix, Marie-Laure, Calvez, Vincent, Descamps, Diane, and Group, ANRS12425 Study

Subjects
HIV integrase inhibitors, NON-nucleoside reverse transcriptase inhibitors, DRUG resistance, ANTIRETROVIRAL agents, MIDDLE-income countries, EBOLA virus
Abstract

Objectives Integrase strand transfer inhibitors (INSTIs) have been recently recommended as the preferred first-line option for antiretroviral treatment initiators in low- and middle-income countries (LMICs) in response to the growing circulation of resistant HIV to non-nucleoside reverse transcriptase inhibitors (NNRTIs). In this study, we estimated the frequency of pretreatment drug resistance (PDR) to INSTIs in West Africa and Southeast Asia. Materials and methods Using samples collected from 2015 to 2016, and previously used to assessed PI, NRTI and NNRTI resistance, we generated HIV integrase sequences and identified relevant INSTI PDR mutations using the Stanford and ANRS algorithms. Results We generated 353 integrase sequences. INSTI PDR frequency was low, 1.1% (4/353) overall, ranging from 0% to 6.3% according to country. However, frequency of PDR to any drug class was very high, 17.9% (95% CI: 13.9%–22.3%), and mostly associated with a high level of NNRTI PDR, 9.7%, and a moderate level of NRTI PDR, 5.3%. Conclusions Our results support the recent introduction of INSTIs in LMICs to improve treatment outcome in these settings, but also stress the need for effective actions to prevent uncontrolled emergence of drug resistance to this drug class. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Defining a dichotomous indicator for population-level assessment of dietary diversity among pregnant adolescent girls and women: a secondary analysis of quantitative 24-h recalls from rural settings in Bangladesh, Burkina Faso, India and Nepal

Author

Verger, Eric O., primary, Eymard-Duvernay, Sabrina, additional, Bahya-Batinda, Dang, additional, Hanley-Cook, Giles T., additional, Argaw, Alemayehu, additional, Becquey, Elodie, additional, Diop, Loty, additional, Gelli, Aulo, additional, Harris-Fry, Helen, additional, Kachwaha, Shivani, additional, Kim, Sunny S., additional, Nguyen, Phuong Hong, additional, Saville, Naomi M., additional, Tran, Lan Mai, additional, Zagré, Rock R., additional, Landais, Edwige, additional, Savy, Mathilde, additional, Martin-Prevel, Yves, additional, and Lachat, Carl, additional

Published
2023
Full Text
View/download PDF

12. Community intervention for child tuberculosis active contact investigation and management: study protocol for a parallel cluster randomized controlled trial

Author

Vasiliu, Anca, Eymard-Duvernay, Sabrina, Tchounga, Boris, Atwine, Daniel, de Carvalho, Elisabete, Ouedraogo, Sayouba, Kakinda, Michael, Tchendjou, Patrice, Turyahabwe, Stavia, Kuate, Albert Kuate, Tiendrebeogo, Georges, Dodd, Peter J., Graham, Stephen M., Cohn, Jennifer, Casenghi, Martina, and Bonnet, Maryline

Published
2021
Full Text
View/download PDF

16. Exploring the magnitude and drivers of the double burden of malnutrition at maternal and dyad levels in peri‐urban Peru: A cross‐sectional study of low‐income mothers, infants and young children

Author

Pradeilles, Rebecca, primary, Landais, Edwige, additional, Pareja, Rossina, additional, Eymard‐Duvernay, Sabrina, additional, Markey, Oonagh, additional, Holdsworth, Michelle, additional, Rousham, Emily K., additional, and M. Creed‐Kanashiro, Hilary, additional

Published
2023
Full Text
View/download PDF

17. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

Author

Reynes, J, Delaporte, E, Koulla-Shiro, S, Ndour, CT, Sawadogo, AB, Seidy, M, Le Moing, V, Calmy, A, Ciaffi, L, Gueye, NF Ngom, Girard, PM, Eholie, S, Guiard-Schmid, JB, Chaix, ML, Kouanfack, C, Tita, I, Bazin, B, Garcia, P, Izard, S, Eymard-Duvernay, S, Peeters, M, Serrano, L, Cournil, A, Mbouyap, PR, Toby, R, Manga, N, Ayangma, L, Mpoudi, M, Zoungrana, Ngole J, Diallo, M, Aghokeng, AF, Guichet, E, Bell, O, Abessolo, H Abessolo, Djoubgang, MR, Manirakiza, G, Lamarre, G, Mbarga, T, Epanda, S, Bikie, A, Nke, T, Massaha, N, Nke, E, Bikobo, D, Olinga, J, Elat, O, Diop, A, Diouf, B, Bara, N, Fall, MB Koita, Kane, C Toure, Seck, FB, Ba, S, Njantou, P, Ndyaye, A, Fao, P, Traore, R, Sanou, Y, Bado, G, Coulibaly, M, Some, E, Some, J, Kambou, A, Tapsoba, A, Sombie, D, Sanou, S, Traore, B, Flandre, P, Michon, C, Drabo, J, Simon, F, Ciaffi, Laura, Koulla-Shiro, Sinata, Sawadogo, Adrien Bruno, Ndour, Cheik Tidiane, Eymard-Duvernay, Sabrina, Mbouyap, Pretty Rosereine, Ayangma, Liliane, Zoungrana, Jacques, Gueye, Ndeye Fatou Ngom, Diallo, Mohamadou, Izard, Suzanne, Bado, Guillaume, Kane, Coumba Toure, Aghokeng, Avelin Fobang, Peeters, Martine, Girard, Pierre Marie, Le Moing, Vincent, Reynes, Jacques, and Delaporte, Eric

Published
2017
Full Text
View/download PDF

19. HIV is associated with airway obstruction: a matched controlled study

Author

Makinson, Alain, Hayot, Maurice, Eymard-Duvernay, Sabrina, Ribet, Céline, Raffi, François, Pialoux, Gilles, Zucman, David, Poizot-Martin, Isabelle, Bonnet, Fabrice, Abgrall, Sophie, Tattevin, Pierre, Cheret, Antoine, Ferry, Tristan, Mauboussin, Jean-Marc, Marchand, Lucie, Rouzaud, Claire, Reynes, Jacques, Zins, Marie, and Le Moing, Vincent

Published
2018
Full Text
View/download PDF

21. Diet and food insecurity among mothers, infants, and young children in Peru before and during COVID‐19: A panel survey

Author

Pradeilles, Rebecca, primary, Pareja, Rossina, additional, Creed‐Kanashiro, Hilary M., additional, Griffiths, Paula L., additional, Holdsworth, Michelle, additional, Verdezoto, Nervo, additional, Eymard‐Duvernay, Sabrina, additional, Landais, Edwige, additional, Stanley, Megan, additional, and Rousham, Emily K., additional

Published
2022
Full Text
View/download PDF

22. Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

Author

Liégeois, Florian, Boyer, S., Eymard-Duvernay, Sabrina, Carrieri, P., Kouanfack, C., Domyeum, J., Maradan, G., Ducos, J., Mpoudi-Ngole, E., Spire, B., Delaporte, E., Kuaban, C., Vidal, Laurent, Laurent, Christian, and EVOLCAM Study Group

Subjects
Treatment, Africa, Testing, HBV, virus diseases, HIV, lcsh:RC109-216, lcsh:Infectious and parasitic diseases
Abstract

Background Hepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients followed up as part of Cameroon’s national antiretroviral programme. Methods A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in 19 hospitals in the Centre and Littoral regions in Cameroon. The proportions of patients tested for hepatitis B surface antigen (HBsAg) prior to the study were compared among all study hospitals using the Chi-square test. The association of individual and hospital-related characteristics with HBV testing and virologic suppression was assessed using multilevel logistic regression models. Results Of 1706 patients (women 74%, median age 42 years, median time on ART 3.9 years), 302 (17.7%) had been tested for HBsAg prior to the study. The proportion of HBV-tested patients ranged from 0.8 to 72.5% according to the individual hospital (p

Published
2020

24. L’offre de boissons, de produits laitiers frais et de biscuits est-elle vraiment plus sucrée aux Antilles qu’en France hexagonale ? [eposter]

Author

Soler, Louis-Georges, Eymard-Duvernay, Sabrina, Rollet, Pascaline, Ducrot, Alexandre, Terrieux, Philippe, Kurtz, Amélie, Méjean, Caroline, Alimentation et sciences sociales (ALISS), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Montpellier Interdisciplinary center on Sustainable Agri-food systems (Social and nutritional sciences) (UMR MoISA), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut de Recherche pour le Développement (IRD)-Centre International de Hautes Etudes Agronomiques Méditerranéennes - Institut Agronomique Méditerranéen de Montpellier (CIHEAM-IAMM), Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro - Montpellier SupAgro, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Direction de l'Alimentation, de l'Agriculture et de la Forêt de Guadeloupe (DAAF Guadeloupe), Direction de l'Alimentation, de l'Agriculture et de la Fôret de Martinique (DAAF Martinique), JFN, Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Perez, Isabelle

Subjects
[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, Martinique, France, Guadeloupe, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Antilles
Abstract

National audience; Introduction et but de l’étude: Dans le prolongement des débats qui ont abouti à la promulgation de la Loi Lurel en 2013 ayant pour objectif d’aligner les teneurs en sucre ajouté de certaines familles de produits vendus dans les régions d'Outre-mer avec celles de produits similaires en France hexagonale, notre étude évalue les teneurs en sucre de l’offre alimentaire disponible de 3 secteurs de produits dans les Antilles et compare cette offre avec celle de l’hexagone.Matériel et méthodes:A partir des données d’étiquetage, en appliquant une démarche similaire à celle de l’Observatoire de l’Alimentation (OQALI) dans l’hexagone, les teneurs en sucres totaux mais aussi le types de marques et le prix des boissons sucrées (BRSA, n=2342), produits laitiers frais (PLF, n=978) et biscuits et gâteaux (BG, n=2055) ont été collectés en 2018-2019 en Martinique et en Guadeloupe, dans 24 grandes et moyennes surfaces (GMS) et 30 commerces de proximité , échantillonnés pour s’assurer d’une bonne représentativité. Pour les comparaisons avec la France Hexagonale, les données de l’OQALI ont été utilisées (respectivement pour les BRSA, PLF et BG, n=3156, n=1918 et n=2046).Résultats et Analyse statistique: Un test de Mann-Whitney a été utilisé pour comparer les teneurs en sucre des produits de l’hexagone et celles des produits des Antilles. Les relations entre prix et teneurs en sucre, types de marque et types de magasins ont été évaluées à l’aide de modèles de régressions linéaires.Pour les 3 secteurs étudiés, l’offre de produits disponible aux Antilles ne se démarque pas de façon importante de celle observée sur le marché hexagonal. Les teneurs moyennes en sucre sont comparables, tant pour le secteur des boissons sucrées (écart moyen de 0,4g/100mL soit 5% d’écart) que pour celui des biscuits et gâteaux (écart moyen de 1.6g/100g soit 3% d’écart). Le secteur des produits laitiers frais se démarque toutefois avec une teneur moyenne en sucres supérieure de 13% (écart moyen de 1.6g/100g) à celle de l’hexagone. De plus, les boissons aux fruits gazeuses et plates, les limonades, les crèmes dessert, les fromages frais et les yaourts sucrés, qui représentent des familles de produits avec de grands nombres de références disponibles (suggérant de hauts niveaux de consommation), ont des teneurs en sucres plus élevées aux Antilles qu’en France Hexagonale. Ces écarts sont susceptibles d’avoir des impacts sur les apports en sucre des consommateurs. De plus, la teneur en sucres des BRSA, des jus et nectars et des PLF est plutôt associée à un prix plus élevé, cet effet est faible en comparaison du poids des marques ou des circuits de distribution sur les prix.Conclusion:Si quelques différences apparaissent clairement et ne doivent pas être sous-estimées, les résultats conduisent à nuancer l’idée que la qualité de l’offre disponible aux Antilles serait le déterminant majeur des apports en sucres plus élevés que dans l’hexagone.

Published
2021

25. Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis

Author

Monnin, Audrey, Vizeneux, Amélie, Nagot, Nicolas, Eymard-Duvernay, Sabrina, Meda, Nicolas, Singata-Madliki, Mandisa, Ndeezi, Grace, Tumwine, James K, Kankasa, Chipepo, Goga, Ameena, Tylleskär, Thorkild, Van de Perre, Philippe, Molès, Jean-Pierre, Salvy-Córdoba, Nathalie, Etablissement Français du Sang [Occitanie] (EFS Occitanie), Université des Antilles (UA), Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier], Centre Muraz [Bobo-Dioulasso, Burkina Faso], University of Fort Hare, Makerere University [Kampala, Ouganda] (MAK), Kabale University School of medicine (KABSOM), University of Zambia [Lusaka] (UNZA), Centers for Disease Control and Prevention [Pretoria, South Africa] (CDC-South Africa), Centers for Disease Control and Prevention (CDC), and University of Bergen (UiB)

Subjects
[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, growth, virus diseases, HIV, mitochondrial DNA, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, Pediatrics, Article, RJ1-570, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, children, telomere shortening, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, neuropsychological development, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Africa, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, prophylaxis, Prophylaxis HIV
Abstract

Telomere shortening can be enhanced upon human immunodeficiency virus (HIV) infection and by antiretroviral (ARV) exposures. The aim of this study was to evaluate the acute and long-term effect on telomere shortening of two ARV prophylaxes, lopinavir/ritonavir (LPV/r) and lamivudine (3TC), administered to children who are HIV-exposed uninfected (CHEU) to prevent HIV acquisition through breastfeeding during the first year of life, and to investigate the relationship between telomere shortening and health outcomes at six years of age. We included 198 CHEU and measured telomere length at seven days of life, at week-50 and at six years (year-6) using quantitative polymerase chain reaction. At week-50, telomere shortening was observed among 44.3% of CHEU, irrespective of the prophylactic treatment. Furthermore, this telomere shortening was neither associated with poor growth indicators nor neuropsychological outcomes at year-6, except for motor abilities (MABC test n = 127, β = −3.61, 95%CI: −7.08, −0.14, p = 0.04). Safety data on telomere shortening for infant HIV prophylaxis are scarce. Its association with reduced motor abilities deserves further attention among CHEU but also HIV-infected children receiving ARV treatment.

Published
2021
Full Text
View/download PDF

26. Are drinks, fresh dairy products and biscuits really sweeter in the West Indies than in mainland France?

Author

Soler, Louis-Georges, Eymard Duvernay, Sabrina, Rollet, Pascaline, Ducrot, Alexandre, Terrieux, Philippe, Kurtz, Amélie, Méjean, Caroline, Alimentation et sciences sociales (ALISS), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Montpellier Interdisciplinary center on Sustainable Agri-food systems (Social and nutritional sciences) (UMR MoISA), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut de Recherche pour le Développement (IRD)-Centre International de Hautes Etudes Agronomiques Méditerranéennes - Institut Agronomique Méditerranéen de Montpellier (CIHEAM-IAMM), Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Direction de l'Alimentation, de l'Agriculture et de la Forêt de Guadeloupe (DAAF Guadeloupe), Direction de l'Alimentation, de l'Agriculture et de la Fôret de Martinique (DAAF Martinique), Cette étude fait partie du projet NuTWInd (Nutrition Transition in French West Indies), financé par l’Agence nationale de la recherché (ANR), ANR-16-CE21-0009,NuTWInd,Transition Nutritionnelle aux Antilles Françaises : Interactions entre offre et comportements alimentaires(2016), Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro - Montpellier SupAgro, and Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)

Subjects
Soft-drinks, West Indies, Biscuits, Teneurs en sucre, Boissons, Fresh dairy products, Produits laitiers, Cookies, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Sugar content, Antilles
Abstract

International audience; In line with the debates that led to the enactment of the Lurel Law in 2013, our study assesses the nutritional quality of products, through their sugar content, for a large part of the food supply available in the French West Indies and compares this food supply with those in mainland France. The analysis focuses on three product sectors - sweetened beverages, fresh dairy products, biscuits and cakes - which are the largest contributors to the sugar intake in populations of Martinique and Guadeloupe. In overall, for the 3 sectors studied, the food supply available in the French West Indies slightly differs from that observed in mainland France. On average, the sugar contents are comparable, both for the sector of sweetened beverages (5% different on average) and for the sector of biscuits and cakes. The sector of fresh dairy products stands out more strongly with an average sugar content of 15% higher than those in mainland France.Nevertheless, for some product groups, which can be widely consumed, variations in sugar content are likely to have an impact on consumers’ sugar intake. Carbonated and non-carbonated fruit drinks, lemonades, creamy desserts, fresh cheeses and sweetened yogurts, which represent groups with a large number of references available (suggesting high levels of consumption), have higher sugar contents in the French West Indies than in mainland France. While these differences clearly appear and should not be underestimated, the results lead to qualify the idea that the nutritional quality of the food supply available in the French West Indies would be a major determinant of higher sugar intakes compared to mainland France. The effect due to the quantities consumed is at least as important as those due to the observed differences in sugar content.; Dans le prolongement des débats qui ont abouti à la promulgation de la Loi Lurel en 2013, notre étude évalue la qualité nutritionnelle des produits appréhendée à travers leur teneur en sucre, pour une large partie de l’offre alimentaire disponible dans les Antilles, et compare cette offre avec celle correspondante dans l’Hexagone. L’analyse se focalise sur trois secteurs de produits - les boissons sucrées, les produits laitiers frais, les biscuits et gâteaux - qui sont les plus gros contributeurs aux apports en sucres des populations en Martinique et Guadeloupe. D’une façon générale, pour les 3 secteurs étudiés, l’offre de produits disponible aux Antilles ne se démarque pas de façon très importante de celle observée sur le marché hexagonal. En moyenne les teneurs en sucres sont comparables, tant pour le secteur des boissons sucrées (5 % d’écart en moyenne) que pour celui des biscuits et gâteaux. Le secteur des produits laitiers frais se démarque plus fortement avec une teneur moyenne en sucres supérieure de 15 % à celle de l’hexagone. Il faut néanmoins noter que, pour quelques familles de produits qui peuvent être largement consommées, les écarts de teneur en sucres sont susceptibles d’avoir des impacts sur les apports en sucres des consommateurs. Boissons aux fruits gazeuses et plates, limonades, crèmes dessert, fromages frais et yaourts sucrés, qui représentent des familles de produits avec de grands nombres de références disponibles (suggérant de hauts niveaux de consommation), présentent ainsi des teneurs en sucres plus élevées aux Antilles qu’en France hexagonale. Si ces différences apparaissent clairement et ne doivent pas être sous-estimées, les résultats conduisent à nuancer l’idée que la qualité de l’offre disponible aux Antilles serait le déterminant majeur des apports en sucre plus élevés que dans l’hexagone. En tout état de cause, l’effet lié aux quantités consommées est au moins aussi important que celui lié aux différences de teneur en sucres observées.

Published
2021

29. Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy

Author

Lê, Minh Patrick, Landman, Roland, Koulla-Shiro, Sinata, Charpentier, Charlotte, Sow, Papa-Salif, Diallo, Mamadou-Baila, Ngom Gueye, Ndèye Fatou, Ngolle, Maguy, Le Moing, Vincent, Eymard-Duvernay, Sabrina, Benalycherif, Aïda, Delaporte, Eric, Girard, Pierre-Marie, Peytavin, Gilles, Landman, R., Peytavin, G., Charpentier, C., Koulla-Shiro, S., Ngolle, M., Kouanfack, C., Ymele, B., Elad, O., Sow, P. S., Diallo, M. B., Ouattara, A., Thiam, A., Ndiaye, B., Fall, M. B. Koita, Essomba, C., Diop, H., Gueye, F. Ngom, Sock, A., Legac, S., Simen, E., Maynart, M., Le Moing, V., Eymard-Duvernay, S., Kane, C. Toure, Benalycherif, A., Aghokeng, A., Delaporte, E., and Girard, P. M.

Published
2015
Full Text
View/download PDF

30. Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso

Author

Mennecier, Anaïs, primary, Kankasa, Chipepo, additional, Fao, Paulin, additional, Moles, Jean-Pierre, additional, Eymard-Duvernay, Sabrina, additional, Mwiya, Mwiya, additional, Kania, Dramane, additional, Chunda-Liyoka, Catherine, additional, Sakana, Leticia, additional, Rutagwera, David, additional, Tassembedo, Souleymane, additional, Wilfred-Tonga, Maria Melany, additional, Mosqueira, Beatriz, additional, Tylleskär, Thorkild, additional, Nagot, Nicolas, additional, and Van de Perre, Philippe, additional

Published
2021
Full Text
View/download PDF

31. Additional file 1 of Community intervention for child tuberculosis active contact investigation and management: study protocol for a parallel cluster randomized controlled trial

Author

Vasiliu, Anca, Eymard-Duvernay, Sabrina, Tchounga, Boris, Atwine, Daniel, Carvalho, Elisabete De, Sayouba Ouedraogo, Kakinda, Michael, Tchendjou, Patrice, Stavia Turyahabwe, Kuate, Albert Kuate, Tiendrebeogo, Georges, Dodd, Peter J., Graham, Stephen M., Cohn, Jennifer, Casenghi, Martina, and Bonnet, Maryline

Subjects
Data_FILES, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Additional file 1. List of participating clusters.

Published
2021
Full Text
View/download PDF

34. Community Intervention for Child Tuberculosis Active Contact Investigation and Management: study protocol for a parallel cluster randomized controlled trial

Author

Vasiliu, Anca, primary, Eymard-Duvernay, Sabrina, additional, Tchounga, Boris, additional, Atwine, Daniel, additional, de Carvalho, Elisabete, additional, Ouedraogo, Sayouba, additional, Kakinda, Michael, additional, Tchendjou, Patrice, additional, Turyahabwe, Stavia, additional, Kuate, Albert Kuate, additional, Tiendrebeogo, Georges, additional, Dodd, Peter J, additional, Graham, Stephen M, additional, Cohn, Jennifer, additional, Casenghi, Martina, additional, and Bonnet, Maryline, additional

Published
2021
Full Text
View/download PDF

35. Regular users of supermarkets in greater tunis have a slightly improved diet quality

Author

Tessier, Sophie, Traissac, Pierre, Maire, Bernard, Bricas, Nicolas, Eymard-Duvernay, Sabrina, Ati, Jalila El, and Delpeuch, Francis

Subjects
Supermarkets -- Research, Consumers -- Food and nutrition, Food/cooking/nutrition
Abstract

Despite the recent and rapid expansion of supermarkets in developing countries, their association with diet quality has been hardly studied. The study took place in Tunisia, where incidences of obesity and nutrition-related diseases are rising. The target population was households of the Greater Tunis area where supermarkets are mostly located. Households (n = 724) were selected by a 2-stage clustered random sampling. A purposely developed quantitative questionnaire assessed food retail habits. Socioeconomic data were collected at individual and household levels. The diet quality index-international (DQI-I) derived from a FFQ specific for Tunisia measured diet quality. Data analysis by regression or logistic regression models adjusted for energy intake and socioeconomic confounders when relevant. Overall, 60% of the households used supermarkets. Most households still used the nearby grocer; only 26% shopped at the market. Characteristics associated with supermarket use were urban milieu, small-sized households, greater educational attainment, higher economic level, steady income, or easy access. Associations between these variables and using supermarkets as a first shopping place (20% of households) were even stronger. After adjustment for energy intake and socioeconomic and access data, using supermarkets chosen as first food shopping place vs. other retail resulted in a slightly higher DQI-I (63.2 vs. 59.6; P = 0.0004). Despite the long-standing presence of supermarkets in Tunis, shopping at supermarkets has not yet spread to the whole population. Supermarkets do not yet markedly modify food consumption in the Greater Tunis. However, a slight improvement of diet quality can be observed among those people who use supermarkets regularly.

Published
2008

36. Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year

Author

Monnin, Audrey, Nagot, Nicolas, Eymard-Duvernay, Sabrina, Meda, Nicolas, Tumwine, James, Tylleskär, Thorkild, Perre, Philippe Van De, Molès, Jean-Pierre, Boutin, Marion, Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre Muraz [Bobo-Dioulasso, Burkina Faso], Department of Paediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda, and University of Bergen (UiB)

Subjects
neurodevelopment, depletion, breastfeeding, growth, [SDV]Life Sciences [q-bio], lcsh:R, lcsh:Medicine, lopinavir/ritonavir, mitochondrial DNA, Article, [SDV] Life Sciences [q-bio], Africa, HIV-exposed uninfected children, lamivudine, ComputingMilieux_MISCELLANEOUS
Abstract

Infant antiretroviral (ARV) prophylaxis given to children who are human immunodeficiency virus (HIV)-exposed but uninfected (CHEU) to prevent HIV transmission through breastfeeding previously proved its efficacy in the fight against the pediatric epidemic. However, few studies have investigated the short- and long-term safety of prophylactic regimens. We previously reported a decrease of mitochondrial DNA (mtDNA) content among CHEU who received one year of lamivudine (3TC) or lopinavir-boosted ritonavir (LPV/r) as infant prophylaxis. We aimed to describe mtDNA content at six years of age among these CHEU, including those for whom we identified mtDNA depletion at week 50 (decrease superior or equal to 50% from baseline), and to compare the two prophylactic drugs. We also addressed the association between mtDNA depletion at week 50 with growth, clinical, and neuropsychological outcomes at year 6. Quantitative PCR was used to measure mtDNA content in whole blood of CHEU seven days after birth, at week 50, and at year 6. Among CHEU with identified mtDNA depletion at week 50 (n = 17), only one had a persistent mtDNA content decrease at year 6. No difference between prophylactic drugs was observed. mtDNA depletion was not associated with growth, clinical, or neuropsychological outcomes at year 6. This study brought reassuring data concerning the safety of infant 3TC or LPV/r prophylaxis.

Published
2020

37. Multimorbidity in elderly persons according to the year of diagnosis of human immunodeficiency virus infection : a cross-sectional dat&8217;aids cohort study

Author

Demontès, M., Eymard-Duvernay, Sabrina, Allavena, C., Jovelin, T., Reynes, J., Hentzien, M., Ravaux, I., Delobel, P., Bregigeon, S., Rey, D., Ferry, T., Gagneux-Brunon, A., Robineau, O., Pugliese, P., Duvivier, C., Cabié, A., Chirouze, C., Jacomet, C., Lamaury, I., Merrien, D., Hoen, B., Hocqueloux, L., Cheret, A., Katlama, C., Arvieux, C., Krolak-Salmon, P., Makinson, A., and Delaporte, Eric

Abstract

Background : We assessed prevalence of multimorbidity (MM) according to year of human immunodeficiency virus (HIV) diagnosis in elderly people living with HIV (PLWH). Methods : This was a cross-sectional study of MM in PLWH aged >-70 years from the Dat'AIDS French multicenter cohort. MM was defined as at least 3 coexistent morbidities of high blood pressure, diabetes mellitus, osteoporosis, non-AIDS cancer, chronic renal failure, cardiovascular and cerebrovascular disease, obesity, undernutrition, or hypercholesterolemia. Logistic regression models evaluated the association between MM and calendar periods of HIV diagnosis (1983-1996, 1997-2006, and 2007-2018). The secondary analysis evaluated MM as a continuous outcome, and a sensitivity analysis excluded PLWH with nadir CD4 count

Published
2020

38. Diet quality of North African migrants in France partly explains their lower prevalence of diet-related chronic conditions relative to their native French peers

Author

Mejean, Caroline, Traissac, Pierre, Eymard-Duvernay, Sabrina, El Ati, Jalila, Delpeuch, Francis, and Maire, Bernard

Subjects
Immigrants -- Food and nutrition, Immigrants -- Health aspects, Food habits -- Evaluation, Food/cooking/nutrition
Abstract

Mediterranean migrant men living in France have lower mortality and morbidity than local-born populations for nutrition-related noncommunicable diseases (NR-NCD). We studied diet quality and its influence on NR-NCD in Tunisian migrants compared with 2 nonmigrant male groups: local-born French and nonmigrant Tunisians, using a retrospective cohort study. We performed quota sampling (n = 147) based on age and place of residence. Using logistic regression models, components of the Diet Quality Index-International (DQI-I) were tested as potential mediators for the effect of migration on overweight, hypertension, hypercholesterolemia, type-2 diabetes, and cardiovascular diseases (CVD). The total DQI-I score revealed good overall diet quality (~60/100) for all groups. Migrants scored higher than the French in variety, adequacy, and moderation and lower than Tunisians in overall balance. Migrants displayed a lower prevalence of overweight than French, lower prevalence of diabetes and CVD than Tunisians, and lower prevalence of hypertension and hypercholesterolemia than the 2 nonmigrant groups. No mediator was found for overweight. Diet adequacy, fruits, and vitamin C were mediators of the difference in hypercholesterolemia between migrants and French and the effect on hypertension was mediated by diet adequacy and fiber. Compared with Tunisians, the effect of migration on hypercholesterolemia was mediated by saturated fat. No mediator was found for hypertension, diabetes, or CVD. Despite increasing NR-NCD levels in both France and Tunisia, migrants appear to have conserved some healthy dietary characteristics that partly explain their difference in NR-NCD with local-born French, but other lifestyle factors may contribute to the favorable effect of migration.

Published
2007

39. Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort Study

Author

Demontès, Marie, Eymard Duvernay, Sabrina, Allavena, Clotilde, Jovelin, Thomas, Reynes, Jacques, Hentzien, Maxime, Ravaux, Isabelle, Delobel, Pierre, Bregigeon, Sylvie, Rey, David, Ferry, Tristan, Gagneux-Brunon, Amandine, Robineau, Olivier, Pugliese, Pascal, Duvivier, Claudine, Cabié, André, Chirouze, Catherine, Jacomet, Christine, Lamaury, Isabelle, Merrien, Dominique, Hoen, Bruno, Hocqueloux, Laurent, Cheret, Antoine, Katlama, Christine, Arvieux, Cédric, Krolak-Salmon, Pierre, Makinson, Alain, Drobacheff-Thiébaut, C, Foltzer, A, Bouiller, K, Hustache- Mathieu, L, Chirouze, C, Lepiller, Q, Bozon, F, Babre, O, Brunel, S, Muret, P, Laurichesse, H, Lesens, O, Vidal, M, Mrozek, N, Aumeran, C, Baud, O, Corbin, V, Letertre-Gibert, P, Casanova, S, Prouteau, J, Jacomet, C, Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Herrmann-Storck, C, Tressieres, B, Bonijoly, T, Receveur, C, Boulard, F, Daniel, C, Clavel, C, Merrien, D, Perré, P, Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Laine, L, Ader, F, Becker, A, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Miailhes, P, Perpoint, T, Roux, S, Triffault-Fillit, C, Degroodt, S, Brochier, C, Valour, F, Chidiac, C, Ménard, A, Belkhir, Y, Colson, P, Dhiver, C, Madrid, A, Martin-Degiovani, M, Meddeb, L, Mokhtari, M, Motte, A, Raoux, A, Ravaux, I, Tamalet, C, Toméi, C, Tissot Dupont, H, Brégigeon, S, Zaegel-Faucher, O, Obry-Roguet, V, Laroche, H, Orticoni, M, Soavi, J, Geneau de Lamarlière, P, Ressiot, E, Ducassou, J, Jaquet, I, Galie, S, Galinier, A, Martinet, P, Landon, M, Ritleng, S, Ivanova, A, Debreux, C, Lions, C, Poizot-Martin, I, Abel, S, Cabras, O, Cuzin, L, Guitteaud, K, Illiaquer, M, Pierre-François, S, Osei, L, Pasquier, J, Rome, K, Sidani, E, Turmel, M, Varache, C, Cabié, A, Atoui, N, Bistoquet, M, Delaporte, E, Le Moing, V, Makinson, A, Meftah, N, Merle de Boever, C, Montes, B, Montoya Ferrer, A, Tuaillon, E, Reynes, J, André, M, Boyer, L, Bouillon, P, Delestan, M, Rabaud, C, May, T, Hoen, B, Allavena, C, Bernaud, C, Billaud, E, Biron, C, Bonnet, B, Bouchez, S, Boutoille, D, Brunet-Cartier, C, Deschanvres, C, Hall, N, Jovelin, T, Morineau, P, Reliquet, V, Sécher, S, Cavellec, M, Soria, A, Ferré, V, André-Garnier, E, Rodallec, A, Lefebvre, M, Grossi, O, Aubry, O, Raffi, F, Pugliese, P, Breaud, S, Ceppi, C, Chirio, D, Cua, E, Dellamonica, P, Demonchy, E, de Monte, A, Durant, J, Etienne, C, Ferrando, S, Garraffo, R, Michelangeli, C, Mondain, V, Naqvi, A, Oran, N, Perbost, I, Pillet, S, Pradier, C, Prouvost-Keller, B, Risso, K, Rio, V, Roger, P, Rosenthal, E, Sausse, S, Touitou, I, Wehrlen-Pugliese, S, Zouzou, G, Hocqueloux, L, Prazuck, T, Gubavu, C, Sève, A, Maka, A, Boulard, C, Thomas, G, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E, Lerolle, N, Deradji, O, Barrail-Tran, A, Landman, R, Joly, V, Ghosn, J, Rioux, C, Lariven, S, Gervais, A, Lescure, F, Matheron, S, Louni, F, Julia, Z, Mackoumbou-Nkouka, C, Le Gac, S, Charpentier, C, Descamps, D, Peytavin, G, Yazdanpanah, Y, Amazzough, K, Avettand-Fenoël, V, Benabdelmoumen, G, Bossi, P, Cessot, G, Charlier, C, Consigny, P, Danion, F, Dureault, A, Duvivier, C, Goesch, J, Guery, R, Henry, B, Jidar, K, Lanternier, F, Loubet, P, Lortholary, O, Louisin, C, Lourenco, J, Parize, P, Pilmis, B, Touam, F, Valantin, M, Tubiana, R, Agher, R, Seang, Sophie, Schneider, L, Palich, R, Blanc, C, Katlama, C, Berger, J, N’guyen, Y, Lambert, D, Kmiec, I, Hentzien, M, Brunet, A, Brodard, V, Bani-Sadr, F, Tattevin, P, Revest, M, Souala, F, Baldeyrou, M, Patrat-Delon, S, Chapplain, J, Benezit, F, Dupont, M, Poinot, M, Maillard, A, Pronier, C, Lemaitre, F, Guennoun, C, Poisson-Vanier, M, Sinteff, J, Arvieux, C, Botelho-Nevers, E, Gagneux-Brunon, A, Frésard, A, Ronat, V, Lucht, F, Fischer, P, Partisani, M, Cheneau, C, Priester, M, Batard, L, Bernard-Henry, C, de Mautort, E, Fafi-Kremer, S, Rey, D, Alvarez, M, Biezunski, N, Debard, A, Delpierre, C, Lansalot, P, Lelièvre, L, Martin-Blondel, G, Piffaut, M, Porte, L, Saune, K, Delobel, P, Ajana, F, Aïssi, E, Alcaraz, I, Baclet, V, Bocket, L, Boucher, A, Choisy, P, Huleux, T, Lafon-Desmurs, B, Meybeck, A, Pradier, M, Robineau, O, Viget, N, Valette, M, Hospices Civils de Lyon (HCL), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Université de Nantes (UN), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Reims (CHU Reims), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Pathogénie des Staphylocoques – Staphylococcal Pathogenesis, Centre International de Recherche en Infectiologie - UMR (CIRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Université de Saint-Etienne, Service Universitaire des Maladies Infectieuses et du Voyageur [Tourcoing], Centre Hospitalier Tourcoing, Service de Maladies Infectieuses [Nice], Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Service de Maladies Infectieuses et Tropicales [Fort-de-France, Martinique], CHU de la Martinique [Fort de France]-Hôpital Pierre Zobda-Quitman [CHU de la Martinique], CHU de la Martinique [Fort de France]-Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Département des Maladies Infectieuses et Tropicales [CHU Gabriel-Montpied, Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Pointe-à-Pitre/Abymes [Guadeloupe], Centre Hospitalier Compiègne-Noyon, Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG), Centre Hospitalier Régional d'Orléans (CHR), Services des maladies infectieuses [CH Turcoing], Centre Hospitalier de Tourcoing, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Besançon (CHU Besançon), Université libre de Bruxelles (ULB), Hôpital Gabriel Montpied, Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Clermont-Ferrand, Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Université d'Auvergne - Clermont-Ferrand I (UdA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), CCLIN Sud-Est – Centre de Coordination de la Lutte contre les Infections Nosocomiales Sud-Est, Service de Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville, Laboratoire Traitement et Communication de l'Information (LTCI), Télécom ParisTech-Institut Mines-Télécom [Paris] (IMT)-Centre National de la Recherche Scientifique (CNRS), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Institut de biologie et chimie des protéines [Lyon] (IBCP), Hôpital de la Croix-Rousse [CHU - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Equipe 15, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Laboratoire de Mécanique et Technologie (LMT), École normale supérieure - Cachan (ENS Cachan)-Centre National de la Recherche Scientifique (CNRS), Centre interrégional de référence Rhône-Alpes - Auvergne des infections ostéo-articulaires complexes, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Assistance Publique - Hôpitaux de Marseille (APHM), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Space Research Institute of the Russian Academy of Sciences (IKI), Russian Academy of Sciences [Moscow] (RAS), DDSIS 76, Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre IRD de Montpellier (IRD), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Bell Labs (BELL), Lucent Technologies, Centre hospitalier universitaire de Nantes (CHU Nantes), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Université Clermont Auvergne (UCA)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service des maladies infectieuses et tropicales [CHU Nantes], Océan du Large et Variabilité Climatique (OLVAC), Laboratoire d'études en Géophysique et océanographie spatiales (LEGOS), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National d'Études Spatiales [Toulouse] (CNES)-Observatoire Midi-Pyrénées (OMP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Plant Biomechanics Group, Botanischer Garten, Albert-Ludwigs-Universität Freiburg, Hôtel-Dieu de Nantes, Service de virologie [CHU Nantes], Département Etude des Réacteurs (DER), CEA-Direction des Energies (ex-Direction de l'Energie Nucléaire) (CEA-DES (ex-DEN)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Service des maladies infectieuses, Centre Hospitalier Universitaire de Nice (CHU Nice)-University Hospital, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, Public Health Department, Hôpital de l'Archet, Institut de génétique humaine (IGH), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Infectious Diseases Department, Université Montpellier 1 (UM1), Environnements et Paléoenvironnements OCéaniques (EPOC), Observatoire aquitain des sciences de l'univers (OASU), Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-École pratique des hautes études (EPHE)-Centre National de la Recherche Scientifique (CNRS), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Régional de recherche et de Formation à la prise en charge Clinique de Fann (CRCF), CHNU Fann, Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Etudes Lasers Intenses et Applications (CELIA), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Sciences et Technologies, Laboratoire de Virologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Pathogénie des infections systémiques (UMR_S 570), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Service des maladies infectieuses [CHU Pitié-Salêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], McGill University, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôpitaux Universitaires de Strasbourg (HUS), Service de pneumologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre de Physique des Particules de Marseille (CPPM), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Aix Marseille Université (AMU), CHU Pontchaillou [Rennes], SEV, Groupe d'Etudes et de Contrôle des Variétés et des Semences (GEVES), Service de virologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], CHU Saint-Etienne, University Hospital and University Jean Monnet, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de Virologie [Strasbourg], Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, CHU de Fort de France, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Université de Montpellier (UM), Service des Maladies Infectieuses et Tropicales [Hôpital de la Conception] (SMIT), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Centre de Physiopathologie Toulouse Purpan (CPTP - U1043 INSERM - UMR5282 CNRS - UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Strasbourg, Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet [Saint-Étienne] (UJM), Centre d'investigation clinique Antilles-Guyane (CIC - Antilles Guyane), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU de la Martinique [Fort de France]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], CHD Vendee (La Roche Sur Yon), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre de Physiopathologie Toulouse Purpan (CPTP), Pathogénie des Staphylocoques – Staphylococcal Pathogenesis (StaPath), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique [Fort de France]-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service des Maladies Infectieuses et Tropicales [CHU Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Centre Hospitalier Régional d'Orléans (CHRO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Jean Monnet - Saint-Étienne (UJM), Institut Pasteur [Paris] (IP), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre Médical de l'Institut Pasteur, Service des maladies infectieuses et réanimation médicale [Rennes], Département Maladies Infectieuses et Tropicales, Hôpital Universitaire, Montpellier, France, Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire Marseille, CHU Marseille, School of Civil and Environmental Engineering [Sydney], University of New South Wales [Sydney] (UNSW), Laboratoire d'Ingénierie Circulation Transport (LICIT UMR TE ), École Nationale des Travaux Publics de l'État (ENTPE)-Université de Lyon-Université Gustave Eiffel, Institut Cochin (IC UM3 (UMR 8104 / U1016)), CHU de la Martinique [Fort de France], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Clermont-Ferrand, Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] (THERAVIR), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)

Subjects
Male, 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, multimorbidity, [SDV]Life Sciences [q-bio], HIV Infections, comorbidities, elderly, Cachexia, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Acquired immunodeficiency syndrome (AIDS), [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Diabetes mellitus, medicine, Humans, 030212 general & internal medicine, Aged, 2. Zero hunger, Acquired Immunodeficiency Syndrome, business.industry, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, aging, virus diseases, HIV, medicine.disease, 030112 virology, Comorbidity, Obesity, CD4 Lymphocyte Count, 3. Good health, Cross-Sectional Studies, Infectious Diseases, Cohort, Coinfection, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Cohort study
Abstract

Background We assessed prevalence of multimorbidity (MM) according to year of human immunodeficiency virus (HIV) diagnosis in elderly people living with HIV (PLWH). Methods This was a cross-sectional study of MM in PLWH aged ≥70 years from the Dat’AIDS French multicenter cohort. MM was defined as at least 3 coexistent morbidities of high blood pressure, diabetes mellitus, osteoporosis, non-AIDS cancer, chronic renal failure, cardiovascular and cerebrovascular disease, obesity, undernutrition, or hypercholesterolemia. Logistic regression models evaluated the association between MM and calendar periods of HIV diagnosis (1983–1996, 1997–2006, and 2007–2018). The secondary analysis evaluated MM as a continuous outcome, and a sensitivity analysis excluded PLWH with nadir CD4 count Results Between January 2017 and September 2018, 2476 PLWH were included. Median age was 73 years, 75% were men, median CD4 count was 578 cells/μL, and 94% had controlled viremia. MM prevalence was 71%. HBP and hypercholesterolemia were the most prevalent comorbidities. After adjustment for age, gender, smoking status, hepatitis C and hepatitis B virus coinfection, group of exposure, nadir CD4 count, CD4:CD8 ratio, and last CD4 level, calendar period of diagnosis was not associated with MM (P = .169). MM was associated with older age, CD4/CD8 ratio Conclusions MM prevalence was high and increased with age, low CD4/CD8 ratio, and nadir CD4 count

Published
2019

40. Dietary diversity scores and nutritional status of women change during the seasonal food shortage in rural Burkina Faso

Author

Savy, Mathilde, Martin-Prevel, Yves, Traissac, Pierre, Eymard-Duvernay, Sabrina, and Delpeuch, Francis

Subjects
Women -- Surveys, Women -- Social aspects, Women -- Nutritional aspects, Food/cooking/nutrition
Abstract

In developing countries, dietary diversity is usually assessed during a single yearly period and the effects of seasonal variations remain unknown. We studied these variations in women living in a Sahelian rural area (Burkina Faso). A representative sample of 550 women was surveyed at the beginning and at the end of the seasonal cereal shortage in April and September 2003, respectively. For each season, a dietary diversity score (DDS) representing the number of food groups consumed over a 24-h period, was computed and nutritional status was assessed by the BMI. The DDS increased from 3.4 [+ or -] 1.1 to 3.8 [+ or -] 1.5 food groups between the beginning and the end of the shortage season (P < 0.0001), and the proportion of women exhibiting low DDS decreased from 31.6 to 8.1%. This was due to the consumption of foods available during the cereal shortage season and despite the decrease in the consumption of some purchased foods. The increase in DDS was lower in women for whom DDS was already high in April and vice versa. Over the same period, the percentage of underweight women (BMI

Published
2006

42. Community Intervention for Child Tuberculosis Active Contact Investigation and Management: Study Protocol for A Cluster Randomized Trial

Author

Vasiliu, Anca, primary, Eymard-Duvernay, Sabrina, additional, Tchounga, Boris, additional, Atwine, Daniel, additional, de Carvalho, Elisabete, additional, Ouedraogo, Sayouba, additional, Kakinda, Michael, additional, Tchendjou, Patrice, additional, Turyahabwe, Stavia, additional, Kuate, Albert Kuate, additional, Tiendrebeogo, Georges, additional, Dodd, Peter J, additional, Graham, Stephen M, additional, Cohn, Jennifer, additional, Casenghi, Martina, additional, and Bonnet, Maryline, additional

Published
2020
Full Text
View/download PDF

43. Screening, diagnosis and care cascade for viral hepatitis B and C in Yaounde, Cameroon : a qualitative study of patients and health providers coping with uncertainty and unbearable costs

Author

Chabrol, Fanny, Noah, D. N., Tchoumi, E. P., Vidal, Laurent, Kuaban, C., Carrieri, M. P., Boyer, S., March, Laura (collab.), Laurent, Christian (collab.), Liégeois, Florian (collab.), Eymard Duvernay, Sabrina (collab.), and EVOLCam Group

Abstract

Objectives To document patients' and healthcare professionals' (HCP) experiences with hepatitis B virus (HBV) and hepatitis C virus (HCV) diagnosis and care, as well as consequences of these infections on patients' life trajectories in Cameroon, an endemic country in sub-Saharan Africa. Design Qualitative sociological study combining in-depth interviews and observations of medical consultations. Interviews and observations transcripts were thematically analysed according to the following themes: circumstances and perceptions surrounding hepatitis screening, counselling and disclosure, information provided by HCP on hepatitis prevention and treatment, experience of access to care and treatment, social/economic trajectories after diagnosis. Setting HIV and gastroenterology/medical services in two reference public hospitals in Yaounde (Cameroon). Participants 12 patients affected by HBV and/or HCV (co-infected or not with HIV), 14 HCP, 14 state and international stakeholders. Findings Many patients are screened for HBV and HCV at a time of great emotional and economic vulnerability. The information and counselling delivered after diagnosis is limited and patients report feeling alone, distressed and unprepared to cope with their infection. After screening positive, patients struggle with out-of-pocket expenditures related to the large number of tests prescribed by physicians to assess disease stage and to decide whether treatment is needed. These costs are so exorbitant that many decide against clinical and biological follow-up. For those who do pay, the consequences on their social and economic life trajectories are catastrophic. Conclusion Large out-of-pocket expenditures related to biological follow-up and treatment pose a real challenge to receiving appropriate care. Free or reasonably priced access to hepatitis B and C treatments can only be effective and efficient at reducing the hepatitis disease burden if the screening algorithm and the whole pretherapeutic assessment package are simplified, standardised and subsidised by comprehensive national policies orientated towards universal healthcare.

Published
2019

45. Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM)

Author

Liégeois, Florian, Eymard-Duvernay, Sabrina, Boyer, S., Maradan, G., Kouanfack, C., Domyeum, J., Boyer, V., Mpoudi-Ngole, E., Spire, B., Delaporte, E., Vidal, Laurent, Kuaban, C., Laurent, Christian, and Evolcam Study Group

Subjects
virological outcome, Africa, antiretroviral, effectiveness, HIV
Abstract

Objectives In terms of HIV infection, western and central Africa is the second most affected region world-wide, and the gap between the regional figures for the testing and treatment cascade and the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets is particularly worrying. We assessed the prevalence of virological suppression in patients routinely treated in 19 hospitals in Cameroon. Methods A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in the Centre and Littoral regions. The prevalences of virological suppression (mL) were compared among all 19 hospitals using the chi(2) test. Potential individual and health care-related determinants of virological suppression were assessed using multivariate logistic regression models. Results A total of 1700 patients (74% women; median age 41 years; median time on ART 3.7 years) were included in the study. The prevalence of virological suppression was 82.4% overall (95% confidence interval 80.5-84.2%). It ranged from 57.1 to 97.4% according to the individual hospital (P < 0.001). After adjustment, virological suppression was associated with age, CD4 cell count at ART initiation, disclosure of HIV status to family members, interruption of ART for more than two consecutive days, and location of patient's residence and hospital (rural/urban). These factors did not explain the heterogeneity of virological suppression between the study hospitals (P < 0.001). Conclusions The overall prevalence of virological suppression was reassuring. Nevertheless, the heterogeneity of virological suppression among hospitals highlights that, in addition to programme-level data, health facility-level data are crucial in order to tailor the national AIDS programme's interventions with a view to achieving the third UNAIDS 90 target.

Published
2019

46. Intimate partner violence against HIV-positive Cameroonian women : prevalence, associated factors and relationship with antiretroviral therapy discontinuity-results from the ANRS-12288 EVOLCam survey

Author

Fiorentino, Marion, Sagaon Teyssier, Luis, Ndiaye, K., Suzan-Monti, M., Mengue, M. T., Vidal, Laurent, Kuaban, C., March, Laura, Laurent, Christian, Spire, B., Boyer, S., Liégeois, Florian (collab.), Eymard Duvernay, Sabrina (collab.), and EVOLCam Study Group

Subjects
violence, intimate partner, HIV, Cameroon, women, antiretroviral therapy interruption
Abstract

Background: Intimate partner violence in its various forms increases HIV exposure in female victims and potentially jeopardizes the HIV treatment cascade, for instance, by impeding engagement in and adherence to care. Elevated rates of HIV and intimate partner violence are reported in Central Africa. Evidence on the effect of intimate partner violence on antiviral therapy interruption is lacking in Cameroon, where only 330,000 women live with HIV and only 19% of HIV-positive people are virally suppressed. This study aimed to assess the prevalence and factors of intimate partner violence against HIV-positive women and its relationship with antiretroviral therapy interruption > 1 month. Methods: The EVOLCam cross-sectional survey was conducted in 19 hospitals in the Center and Littoral regions. The study sample comprised antiviral therapy-treated women declaring at least one sexual partner in the previous year. Scores of recent emotional, physical, extreme physical and sexual intimate partner violence were built using principal component analysis and categorized under no, occasional or frequent intimate partner violence. Multivariate logistic analyses were performed to investigate the relationship between intimate partner violence and recent antiretroviral therapy interruption > 1 month, and associated factors. Results: Among the 894 analyzed women, the prevalence of intimate partner violence was 29% (emotional), 22% (physical), 13% (extreme physical) and 18% (sexual). Frequent physical intimate partner violence was a significant risk factor of antiretroviral therapy interruption > 1 month (adjusted odds ratio = 2.42 (95% confidence interval = 1.00; 5.87)). It was also associated with HIV-related stigma (2.53 (1.58; 4.02)), living with a main partner (2.03 (1.20; 3.44) and non-defensive violence against this partner (5.75 (3.53; 9.36)). Conclusion: Intimate partner violence is a potential barrier to antiviral therapy continuity and aggravates vulnerability of Cameroonian HIV-positive women. The prevention and detection of intimate partner violence by HIV services might help to reach the last "90" of the 90-90-90 targets.

Published
2019

47. Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries

Author

Ngo-Giang-Huong, Nicole, Huynh, T. H. K., Dagnra, A. Y., Toni, T. D., Maiga, A. I., Kania, D., Eymard-Duvernay, Sabrina, Peeters, Martine, Soulie, C., Peytavin, G., Rekacewicz, C., Chaix, M. L., Aghokeng Fobang, Avelin, Ayouba, Ahidjo (collab.), and ANRS Study Group

Subjects
parasitic diseases, virus diseases
Abstract

Background: ART in the developing world has moved to a new era with the WHO recommendation to test and immediately treat HIV-positive individuals. A high frequency of pretreatment HIV drug resistance (PDR) can compromise ART efficacy. Our study presents updated estimates of PDR in seven countries from West Africa (Burkina Faso, Cameroon, Cate d'Ivoire, Mali and Togo) and Southeast Asia (Thailand and Vietnam). Methods: Eligible study participants were adult ART initiators, recruited from December 2015 to November 2016 in major ART clinics in each country. HIV drug resistance (HIVDR) tests were performed for all specimens and interpretation was done using the Stanford algorithm. Results: Overall, 1153 participants were recruited and 1020 nt sequences were generated. PDR frequency among all initiators was 15.9% (95% CI: 13.8%-18.3%) overall, ranging from 9.6% and 10.2% in Burkina Faso and Thailand, respectively, 14.7% in Vietnam, 15.4% in Mali, 16.5% in Cote d'Ivoire and 19.3% in Cameroon, to 24.6% in Togo. The prevalence of NNRTI resistance mutations was 12%; NRTI and PI PDR prevalences were 4% and 3%, respectively. Conclusions: Our study shows that in most countries PDR exceeded 10%, warranting the conduct of nationally representative surveys to confirm this trend. In the meantime, actions to prevent drug resistance, including transition from NNRTIs to more robust drug classes should be urgently implemented.

Published
2019

50. Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial).

Author

Delaugerre, Constance, Nere, Marie-Laure, Eymard-Duvernay, Sabrina, Armero, Alix, Ciaffi, Laura, Koulla-Shiro, Sinata, Sawadogo, Adrien, Gueye, Ndaye Fatou Ngom, Ndour, Cheik Tidiane, Ngolle, Mireille Mpoudi, Amara, Ali, Chaix, Marie-Laure, Reynes, Jacques, group, the ANRS 12286/MOBIDIP study, Ngom Gueye, Ndaye Fatou, Mpoudi Ngolle, Mireille, and ANRS 12286/MOBIDIP study group

Subjects
PROTEASE inhibitors, ATAZANAVIR, RITONAVIR, SEQUENCE analysis, LAMIVUDINE, VIRAL load, LOGISTIC regression analysis, PATIENTS' attitudes, THERAPEUTIC use of protease inhibitors, ANTI-HIV agents, HIV infections, RESEARCH, GENETIC mutation, RESEARCH methodology, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, DRUG resistance in microorganisms, HIV, PHARMACODYNAMICS
Abstract

Background: The ANRS12286/MOBIDIP trial showed that boosted protease inhibitor (bPI) plus lamivudine dual therapy was superior to bPI monotherapy as maintenance treatment in subjects with a history of M184V mutation.Objectives: We aimed to deep analyse the detection of M184V/I variants at time of switch and at the time of virological failure (VF).Methods: Ultra-deep sequencing (UDS) was performed on proviral HIV-DNA at inclusion among 265 patients enrolled in the ANRS 12026/MOBIDIP trial, and on plasma from 31 patients experiencing VF. The proportion of M184V/I variants was described and the association between the M184V/I mutation at 1% of threshold and VF was explored with logistic regression models.Results: M184V and I mutations were detected in HIV-DNA for 173/252 (69%) and 31/252 (12%) of participants, respectively. Longer duration of first-line treatment, higher plasma viral load at first-line treatment failure and higher baseline HIV-DNA load were associated with the archived M184V. M184I mutation was always associated with a STOP codon, suggesting defective virus. The 48 week estimated probability of remaining free from VF was comparable with or without the M184V/I mutation for dual therapy. At failure, M184V and major PI mutations were detected in 1/17 and 5/15 patients in the bPI arm and in 2/2 and 0/3 in the bPI+lamivudine arm, respectively.Conclusions: Using UDS evidenced that archiving of M184V in HIV-DNA is heterogeneous despite past historical M184V in 96% of cases. The antiviral efficacy of lamivudine-based dual therapy regimens is mainly due to the residual lamivudine activity. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results